Vitamin D for Premature Infants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines whether adding vitamin D to a special baby formula can help premature infants born between 28 to 34 weeks gestation achieve healthier vitamin D levels. The study compares two groups: one receives vitamin D drops with their formula, while the other receives placebo drops (a dummy treatment). Researchers aim to determine if the vitamin D group achieves better vitamin D levels by about one year after their original due date. This trial suits premature infants born at specific hospitals who have transitioned mostly to formula feeding and are no longer on mechanical ventilation.
As an unphased trial, this study provides a unique opportunity to contribute to important research that could improve health outcomes for premature infants.
Will I have to stop taking my current medications?
The trial does not specify if participants must stop taking their current medications, but it does require that infants are no longer receiving mechanical ventilation or diuretics. If your infant is on these treatments, they may need to stop before joining the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that giving vitamin D to infants, including those born early, is generally safe. Studies have found that vitamin D reduces the number of premature babies with low levels of this vitamin. Without extra vitamin D, many premature infants are born with deficiencies. Adding vitamin D significantly lowers these deficiency rates.
Some research has explored higher doses of vitamin D. These studies found that giving preterm infants 800 IU or more each day led to positive results, particularly for bone health. A review of high-dose vitamin D in young children found it to be generally safe.
Most health guidelines recommend that both preterm and full-term infants receive 400 IU of vitamin D daily to support healthy bones. This amount is considered safe and well-tolerated.12345Why are researchers excited about this trial?
Most treatments for premature infants focus on providing essential nutrients through standard formulas and supplements. However, this new approach uses vitamin D drops added directly to transitional formula, which might enhance bone health and immune function more effectively. Researchers are excited because vitamin D is crucial for development, and this method could offer a simple yet impactful way to support growth and health in premature infants, potentially leading to better long-term outcomes.
What evidence suggests that Vitamin D might be an effective treatment for premature infants?
Research has shown that giving vitamin D to premature babies can improve their health. For example, a high dose of vitamin D (800 IU/day or more) has been linked to better short-term growth in weight and length. Studies also indicate that more vitamin D can lower the risk of deficiency in these babies. One study suggested that higher doses of vitamin D are safe and may improve overall health outcomes for premature infants. In this trial, infants in the Investigational Nutrition group will receive vitamin D drops added to their formula, while those in the Routine Nutrition group will receive placebo drops. These findings support the idea that adding vitamin D to special formulas for premature babies could be beneficial.26789
Who Is on the Research Team?
Amy h, MD
Principal Investigator
Baylor College of Medicine
Are You a Good Fit for This Trial?
This trial is for preterm infants born between 28 and 34 weeks gestation, weighing 1000-2250g, who are now 34 to almost 39 weeks post-menstrual age. They should be transitioning to formula feeding and not on mechanical ventilation or diuretics. Infants with severe lung disease requiring daily diuretics, major birth defects, serious intestinal issues, or needing high-calorie formulas can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants receive vitamin D or placebo drops added to transitional formula daily from PMA 34-38 weeks until hospital discharge and at home until 52 weeks PMA
Follow-up
Participants are monitored for serum 25-hydroxyvitamin D levels and bone status at 52 weeks PMA
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Vitamin D
Vitamin D is already approved in United States, European Union, Canada for the following indications:
- Rickets
- Osteomalacia
- Osteoporosis
- Hypocalcemia
- Hyperparathyroidism
- Malabsorption states
- Cirrhosis
- Obesity
- Rickets
- Osteomalacia
- Osteoporosis
- Hypocalcemia
- Hyperparathyroidism
- Malabsorption states
- Cirrhosis
- Obesity
- Rickets
- Osteomalacia
- Osteoporosis
- Hypocalcemia
- Hyperparathyroidism
- Malabsorption states
- Cirrhosis
- Obesity
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor College of Medicine
Lead Sponsor
Mead Johnson Nutrition
Industry Sponsor
The Children's Nutrition Research Center
Collaborator